Tag:
Trubion Pharmaceuticals
Latest Headlines
Latest Headlines
Emergent buys Trubion for up to $135M
Emergent BioSolutions is buying Trubion Pharmaceuticals for $96.8 million up front and up to $38.7 million of success-based milestones. Emergent gains Trubion's two clinical-stage product candidates
Trubion slumps after Pfizer kills lead RA drug program
Shares of Seattle-based Trubion Pharmaceuticals ( TRBN ) slumped after Pfizer announced that it was dumping the development program for its lead rheumatoid arthritis drug. TRU-015 had been Trubion's
Pfizer developing "bio-betters," seeking rare blood disorder drugs
Anyone doubting Big Pharma's interest in developing biotech drugs should check out a new report in the Wall Street Journal detailing Pfizer's work on three large molecules now in mid-stage
Facet, Trubion in $196M collaboration deal
When we last heard from Trubion Pharmaceuticals, the company had just cut 25 percent of its workforce to preserve enough cash to survive the economic downturn. But the company has good news today.
Trubion slashes staff, refocuses R&D
Seattle-based Trubion Pharmaceuticals has become the latest in a long lineup of biotech companies hunkering down, laying off staffers and refocusing on core programs. Trubion says that it will lay
Trubion gains $52M in lackluster IPO
Trubion Pharmaceuticals went public on Tuesday, raising about $52 million as it sold shares at the bottom of its price range. Trubion had outlined plans to raise up to $86 million. Still, just
Trubion announces plans for IPO
Trubion Pharmaceuticals, a 2006 Fierce 15 biotech, has filed an IPO designed to raise up to $86.25 million. Wyeth, which is co-developing TRU-015, has agreed to buy 20 percent of the new shares at
